Stem cells constitute a set of undifferentiated cells with the capacity to differentiate into other cell types and to self-renew. Stem cells can be: (i) totipotent, such as the ones of the zygote, which can give rise to any cell in an organism and to extraembryonic structures; (ii) pluripotent, such as embryonic cells that can differentiate into any cell in the germ layers; (iii) multipotent if they can differentiate into different cell types within specific lineages, such as hematopoietic stem cells; (iv) oligopotent, with the capacity to differentiate into only some cell types; and (v) unipotent, which gives rise to a specific cell type. In adults, there are multipotent, oligopotent and unipotent stem cells, being distributed throughout the organism. Their functions involve maintaining tissue homeostasis and regeneration. These include mesenchymal, hematopoietic, neural and dermal stem cells (MSC, HSC, NSC and DSC, respectively).
For ethical reasons, clinical applications of stem cells are developed mainly using adult stem cells. Fortunately, pluripotent stem cells can be obtained by genetic reprogramming of adult somatic cells. They are called induced pluripotent stem cells (iPSC). Among stem cells, HSCs have been studied for more than 50 years. Their isolations from different sources, such as bone marrow, peripheral blood or umbilical cord blood, have been described and standardized, as well as their use in cell therapy. HSCs are mainly used in transplantation, in patients with an inefficient hematopoietic system, which may be caused by pathologies, such as leukemia or anemia [1].
For their part, MSCs in the last 20 years have become the most studied stem cells, exhibiting the greatest potential for regenerative medicine applications. MSCs were identified in guinea-pig bone marrow and spleen by Friedenstein in 1970, being described as fibroblastic cells with the capacity to differentiate into osteoblasts [2]. Later, it was shown that MSCs can also differentiate into other cell types, derived from the mesoderm, such as adipocytes and chondrocytes. MSCs can even differentiate into cells of endodermal and ectodermal origin, such as hepatocytes and neurons.
MSCs can be obtained from different tissues, including bone marrow, fat tissue, umbilical cord, hair follicle, periodontal ligament and placenta. Once isolated, they must be expanded and characterized for possible therapeutic use. In order to homogenize the criteria defining MSCs, the International Society for Cell Therapy (ISCT) defined their minimum characteristics. Thus, they must: (i) be plastic adherent under standard culture conditions; (ii) express the surface markers CD-73, CD-90 and CD-105; and (iii) lack expression of CD-11b, CD-14, CD-19, CD-34, CD-45, CD-79a and HLADR. In addition, they must have the capacity to differentiate into osteoblasts, adipocytes or chondrocytes in vitro [3]. The main MSC characteristics that define their therapeutic potential are: (i) immunomodulatory activity; (ii) differentiation capacity; (iii) easy isolation from their source and further expansion in vitro; (iv) susceptible to cryopreservation; (v) hypoimmunogenic, expressing low levels of Major Histocompatibility Complex (MHC) class I and II; (vi) susceptible to intravenous administration; and (vii) involved in cell signaling, producing and secreting paracrine factors with regenerative capacity.
Numerous studies have demonstrated the immunomodulatory character of MSCs. Their application in the treatment of different pathologies has evidenced their capacity to regulate the immune response. They have been shown to suppress T-cell proliferation, cytokine secretion and cytotoxicity, regulating the Th1/Th2 balance and the functions of regulatory T cells (Tregs). They also increase B-cell viability and affect antibody secretion and the production of B-cell co-stimulatory molecules. Additionally, they inhibit the maturation and activation of dendritic cells and natural killer (NK) cells induced by interleukin-2 (IL-2). These actions are mediated by secreting immunosuppressive factors, such as TGF-, PGE2 and IL-10 [4].
With regard to their differentiation capacity, MSCs can differentiate into different cell types in vitro, under the appropriate stimuli. Among them are osteoblasts, chondrocytes and adipocytes. This differentiation capacity has allowed the development of very interesting therapeutic strategies. For example, MSCs can be included in biocompatible scaffolds containing factors that induce their differentiation into the desired cell types. Different types of biomaterials have been experimented on for this purpose. They include bioceramics, polymers and composite biomaterials. They must be biocompatible, biodegradable and osteoinductive. Their structure must allow the three-dimensional growth of MSCs, as well as their communication with the tissues surrounding the implant. In relation to added factors, osteoinductive ones may include bone morphogenetic proteins (BMP), fibroblast growth factor (FGF), transforming growth factor-1 (TGFB1) and vascular endothelial growth factor (VEGF). The latter is an important angiogenic factor. It can induce the formation of vessels that supply nutrients and oxygen to the scaffold, thus, ensuring survival of implanted MSCs. These strategies have been evaluated in numerous preclinical studies, as well as several clinical trials, with very promising results. For instance, they have been used in the treatment of difficult-to-heal bone fractures [5].
Implantation of MSCs in tissue-injured areas has shown that a high proportion of MSCs does not participate in tissue regeneration through cell differentiation. Rather, they participate in the creation of a suitable microenvironment, favoring proliferation and differentiation of endogenous cells. For this reason, much interest has been directed in recent years to the paracrine factors secreted by MSC. These factors constitute the MSC secretome, being composed of soluble ones and extracellular vesicles [6]. The former includes cytokines, chemokines, immuno-modulatory molecules and growth factors, such as TGF-, PGE2, IL-10, VEGF, HGF, IGF and FGF. In relation to extracellular vesicles, exosomes of endosomal origin and between 30 and 150 nm in size stand out. They are composed of a lipid bilayer with different membrane proteins. Their cargos include nucleic acids, proteins and different metabolites. Indeed, exosomes are a vehicle of intercellular communication, involved in homeostasis and tissue regeneration, as well as in pathological processes. Extracellular vesicles secreted by MSCs can affect the composition of the extracellular matrix. That can be accomplished through matrix-remodeling enzymes or by cellular physiological processes, after interacting with their host cells. Thus, MSC-derived exosomes can intervene in processes related to tissue regeneration, such as proliferation, differentiation, apoptosis, angiogenesis, migration and immunomodulation, among others.
On the other hand, it is important to note that MSC culture and expansion for use in cell therapy are carried out outside their natural niche. Thus, such conditions may influence their regenerative capacity. Therefore, it is essential to develop suitable culture conditions that allow for their expansion, without impairing their therapeutic properties. The MSC manufacturing process for clinical use should comply with the principles of Good Manufacturing Practice (GMP). This ensures that cell preparations are produced, processed and stored with the necessary controls for clinical use [7]. It should be taken into account that in vitro expansion of MSCs can produce genetic instability in cells. That might favor their potential tumorigenicity when they are implanted in patients. There is also risk of infection during isolation and administration procedures. Other drawbacks include their putative pro-fibrogenic potential and lung entrapment. That is particularly relevant when they must pass through small capillaries. Other potential issues with MSCs in cell therapy include their heterogeneous differentiation ability of distinct MSC populations.
Fortunately, the use of MSC-derived exosomes can bypass some of the limitations of using MSCs for clinical purposes. Among the advantages of the former in regenerative medicine are: (i) can be easily stored; (ii) production of large quantities of cells is not necessary; (iii) can be evaluated for safety, dosage and activity, as conventional pharmaceutical agents; (iv) have a long half-life and stability; (v) can be more easily applied than proliferative cells in the clinic; (vi) can circulate through the smallest capillaries, crossing the bloodbrain barrier; (vii) have lower risks of immune rejection, cellular dedifferentiation or tumor formation than cellular therapies; and (viii) can be manipulated for more precise effects as therapeutic agents [8]. Manipulation of their cargos can be accomplished by MSC preconditioning under certain conditions, favoring the secretion of desired factors; for example, conditions of hypoxia or inflammation, when the aim is to obtain vesicles enriched in angiogenic or immunomodulatory factors [9]. In addition, application of different biotechnological techniques on these vesicles can alter their composition, transforming them into drug-carrying vehicles, with great customized therapeutic potential.
In addition to the development of cell therapy or cell-free therapy, application of stem cells in regenerative medicine can also be performed using other strategies. They include inducing mobilization of the patients stem cells from their reservoirs, such as bone marrow, into damaged tissues [10]. Indeed, this process occurs naturally, upon the occurrence of an injury, such as a skin ulcer, bone fracture or myocardial infarction. One of the main factors involved in stem cell mobilization is SDF-1. This soluble protein binds to its receptor CXCR4, located on the surface of the stem cell membrane. This way, it promotes cell migration into areas with higher concentrations of SDF-1. Under physiological conditions, such a concentration is higher in bone marrow, which maintains progenitor cells in this niche, than in other tissues. Interestingly, upon injury, tissues secrete SDF-1, increasing its concentration and, thus, reversing its previous gradient. In this way, progenitor cells, such as MSCs or endothelial progenitor cells (EPCs), are mobilized outside the bone marrow. Thus, they are directed into the damaged tissue, facilitating its regeneration [11].
On the other hand, there is evidence that aging and certain pathologies, such as diabetes, may decrease the capacity to mobilize progenitor cells. Therefore, therapeutic strategies that favor mobilization of these precursor cells can facilitate regenerative processes, such as, for example, healing chronic ulcers in diabetics [12]. Usually, these strategies are based on the use of drugs that induce stem cell mobilization. Among these compounds are granulocyte colony stimulant (G-CSF) and the CXCR4 antagonist, called plerixafor or AMD3100. It is used to mobilize progenitor cells in peripheral blood after bone marrow transplantation [13]. Recently, it has been shown that other drugs, such as teriparatide (PTH1-34) and DPP4 inhibitors (DPP4i), can favor progenitor-cell mobilization, being, therefore, proposed for regenerative medicine [14,15].
The possibility of using different therapeutic strategies based on stem cells is very promising for progress in regenerative medicine. Yet, there are still many questions to be answered in order to improve the efficiency of these treatments, before they can be widely used. In this scenario, there are numerous challenges to be addressed by basic and clinical research, in order to continue advancing in the development of new treatments, involving the use of stem cells. Among these challenges is the development of homogeneous, reproducible and efficient stem cell isolation, culture and expansion techniques. The same is applicable to the development of cell-free therapies, using extracellular vesicles. In this case, it is also essential to develop appropriate techniques that allow for their production, isolation and conservation, so that they can be used on a large scale in regenerative medicine.
In order to reach these challenges, this Special Issue about stem cells and regenerative medicine in the Journal of Clinical Medicine aims to be a meeting point for the latest advances in basic research, as well as application of stem cells and exosomes in regenerative medicine. Thus, contributing to such knowledge about stem cells and their derivatives should shed light on these exiting topics, which has the potential to improve clinical practice in a safer and more effective manner.
Read more:
Stem Cells in Regenerative Medicine - PMC - National Center for ...
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 15th, 2024
Recent Comments